Northern Trust’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-356,234
| Closed | -$12M | – | 4811 |
|
|
2021
Q2 | $12M | Buy |
356,234
+17,405
| +5% | +$444K | ﹤0.01% | 2241 |
|
|
2021
Q1 | $7.92M | Sell |
338,829
-17,075
| -5% | -$517K | ﹤0.01% | 2452 |
|
|
2020
Q4 | $10.2M | Sell |
355,904
-6,867
| -2% | -$173K | ﹤0.01% | 2235 |
|
|
2020
Q3 | $7.35M | Buy |
362,771
+31,530
| +10% | +$770K | ﹤0.01% | 2297 |
|
|
2020
Q2 | $9.95M | Buy |
331,241
+99,524
| +43% | +$3.58M | ﹤0.01% | 2095 |
|
|
2020
Q1 | $7.28M | Buy |
231,717
+49,844
| +27% | +$1.73M | ﹤0.01% | 2090 |
|
|
2019
Q4 | $8.57M | Buy |
181,873
+26,345
| +17% | +$761K | ﹤0.01% | 2274 |
|
|
2019
Q3 | $1M | Buy |
155,528
+9,170
| +6% | +$76.6K | ﹤0.01% | 3395 |
|
|
2019
Q2 | $1.8M | Buy |
146,358
+16,548
| +13% | +$184K | ﹤0.01% | 3132 |
|
|
2019
Q1 | $1.76M | Buy |
129,810
+78,802
| +154% | +$706K | ﹤0.01% | 3156 |
|
|
2018
Q4 | $204K | Buy |
51,008
+5,624
| +12% | +$33.9K | ﹤0.01% | 3788 |
|
|
2018
Q3 | $306K | Buy |
+45,384
| New | +$432K | ﹤0.01% | 3756 |
|
Northern Trust's CNST Position: Q3 2021 in Review
Northern Trust sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2021, closing a stake of 356,234 shares — an estimated $12M sold.
Northern Trust first reported a position in CNST in Q3 2018 and held it in 12 quarters. The position peaked at $12M in Q2 2021. 0 funds tracked by Wall St. Rank hold CNST as of Q3 2021.
- Northern Trust reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
- Northern Trust sold 356,234 Constellation Pharmaceuticals, Inc. shares in Q3 2021, an estimated $12M.
- Northern Trust first reported a position in Constellation Pharmaceuticals, Inc. in Q3 2018 and held it in 12 quarters.
- Northern Trust's Constellation Pharmaceuticals, Inc. position peaked at $12M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2021.
Based on Northern Trust's 13F filing for Q3 2021, filed 15 Nov 2021.